Hogge Gary S.
Known title: SVP,Clinical & Medical AffairsCIK: 0001771711
Associated companies
Transaction History
| LCTX | ▼ Sell | Tax Withholding | 5,310 | $7K | 2/11/2023 | View on chart |
| LCTX | ▲ Buy | Option Exercise | 13,020 | — | 2/11/2023 | View on chart |
| LCTX | ▼ Sell | Open Market | 28,445 | $69K | 12/29/2021 | View on chart |
| LCTX | ▼ Sell | Open Market | 9,250 | $23K | 12/29/2021 | View on chart |
| LCTX | ▲ Buy | Option Exercise | 9,250 | $6K | 12/29/2021 | View on chart |
| LCTX | ▲ Buy | Option Exercise | 236,899 | $500K | 12/28/2021 | View on chart |
| LCTX | ▲ Buy | Option Exercise | 185,000 | $128K | 12/28/2021 | View on chart |
| LCTX | ▲ Buy | Option Exercise | 79,689 | $91K | 12/28/2021 | View on chart |
| LCTX | ▼ Sell | Open Market | 501,588 | $1.2M | 12/28/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
LCTX Holds Q2 2026 Earnings Conference Call
Lineage Cell Therapeutics held its Q2 2026 earnings conference call, with a transcript released by Benzinga. Management reviewed the quarter's financial results and gave updates on ongoing clinical programs. The discussion provides investors with current insight into the company's performance and future plans. The call occurs while the stock is near its recent support level.
LCTX Holds Q2 2026 Earnings Conference Call. Lineage Cell Therapeutics held its Q2 2026 earnings conference call, with a transcript released by Benzinga. Management reviewed the quarter's financial results and gave updates on ongoing clinical programs. The discussion provides investors with current insight into the company's performance and future plans. The call occurs while the stock is near its recent support level.